KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Investment Securities (2018 - 2020)

Esperion Therapeutics (ESPR) has disclosed Gains from Investment Securities for 3 consecutive years, with $234940.0 as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Gains from Investment Securities rose 188.16% year-over-year to $234940.0, compared with a TTM value of $234940.0 through Mar 2020, up 188.16%, and an annual FY2025 reading of $612000.0, changed N/A over the prior year.
  • Gains from Investment Securities was $234940.0 for Q1 2020 at Esperion Therapeutics, down from $4.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.3 million in Q4 2018 and bottomed at $81530.0 in Q1 2019.
  • Average Gains from Investment Securities over 3 years is $1.8 million, with a median of $419628.0 recorded in 2019.
  • The sharpest move saw Gains from Investment Securities crashed 98.06% in 2019, then soared 188.16% in 2020.
  • Year by year, Gains from Investment Securities stood at $5.3 million in 2018, then dropped by 11.8% to $4.7 million in 2019, then tumbled by 94.98% to $234940.0 in 2020.
  • Business Quant data shows Gains from Investment Securities for ESPR at $234940.0 in Q1 2020, $4.7 million in Q4 2019, and $419628.0 in Q3 2019.